Trial Profile
C-REGS2 - A Registry Study to Observe Clinical Practices, Safety and Efficiency of Routine Use of Cerebrolysin in the Treatment of Patients With Moderate to Severe Neurological Deficits After Acute Ischaemic Stroke
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs FPF 1070 (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms C-REGS2
- Sponsors EVER Neuro Pharma
- 09 Apr 2024 Planned End Date changed from 15 Apr 2024 to 15 May 2024.
- 04 Mar 2024 Planned End Date changed from 30 Sep 2024 to 15 Apr 2024.
- 11 Dec 2023 Planned End Date changed from 30 Apr 2024 to 30 Sep 2024.